IL6 and lung carcinoma: Compared to the SPHK2 inhibitor Opaganib, which only reduces the release of IL-6 from PBMC of lung cancer origin, inhibition of SPHK1 by PF543 can down-regulate both TNF-α and IL-6 release and more effectively inhibit lung cancer progression [45].